Life Sciences: Biotech
'83 law called big boost for rare-disease drugs
WASHINGTON -- More drug companies are embracing the challenge of creating therapies for rare diseases, despite the pint-size potential markets for those drugs. (Full article: 704 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
